Connecting the Dots: Neurobiological Interplay Between Type 2 Diabetes and Alzheimer’s Disease
Authors:
- Analía Foncea-BitránAFAnalía Foncea-Bitrán
- Cristián Barros-OsorioCBCristián Barros-Osorio
- Francisca ArriazaFAFrancisca Arriaza
- Catalina Ramírez-LópezCRCatalina Ramírez-López
- Lina M. RuizLRLina M. Ruiz
- Marlen BarretoMBMarlen Barreto
- Fernando C. OrtizFOFernando C. Ortiz
- Francisca CornejoFCFrancisca Cornejo
- Gonzalo I. GómezGonzalo I. Gómez
Open Access
- 2 April 2026
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3225
Abstract
Diabetes Mellitus is a chronic metabolic disorder characterized by impaired insulin production and/or action, leading to persistent hyperglycemia and insulin resistance. It has been associated with several comorbidities, including cognitive dysfunction, affecting functions such as attention, memory, and processing speed. Mounting evidence indicates a complex relationship between type 2 Diabetes Mellitus (DM2) and neurodegenerative disorders such as mild cognitive impairment and Alzheimer’s disease (AD). Beyond the conventional hallmarks of each pathology, patients with DM2 face an increased risk of neuronal degeneration, while AD is characterized by a marked reduction in insulin receptor density. Although aging, neuroinflammation, and vascular dysfunction have been recognized as key risk factors in AD, the precise molecular mechanisms driving AD pathogenesis remain incompletely understood. Various studies have been conducted to identify reliable biomarkers that elucidate the connection between DM2 and AD, including insulin dysregulation, neuroinflammation, amyloid-β aggregation, and tau hyperphosphorylation. Investigation of these biomarkers is still ongoing, and they may serve not only as diagnostic tools but also as therapeutic targets. Here, we review the current evidence supporting a convergent biological framework between DM2 and AD. Clarifying these shared pathways may improve early detection and guide the development of targeted therapeutic strategies aimed at reducing neurodegeneration in metabolically vulnerable populations.Keywords
All Related Versions
Funding Information
- Fondo Nacional de Desarrollo Científico y Tecnológico (1250485)
This publication has 203 references indexed in Scilit:
- APOE ε4 carrier status and sex differentiate rates of cognitive decline in early‐ and late‐onset Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Human brain and serum advanced glycation end products are highly correlated: Preliminary results of their role in Alzheimer’s disease and type 2 diabetesAlzheimer's & Dementia, 2020
- Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease DementiaJAMA Neurology, 2020
- Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive FunctionAnnals of Neurology, 2020
- Neurodegeneration in type 2 diabetes: Alzheimer's as a case studyBrain and Behavior, 2020
- Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of aging cohortAnnals of Neurology, 2010
- Insulin Resistance and Cognitive ImpairmentArchives of Neurology, 2005
- The Metabolic Syndrome, Inflammation, and Risk of Cognitive DeclineJAMA, 2004
- Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive FunctionArchives of Neurology, 2004
- Insulin receptors and insulin actions in the nervous systemDiabetes/Metabolism Research and Reviews, 2000